{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:14:19Z","timestamp":1785352459099,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06999-x","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T02:47:48Z","timestamp":1776739668000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Donor type and post-transplant outcomes in anti-thymocyte globulin based allogeneic transplantation for myelodysplastic syndromes"],"prefix":"10.1007","volume":"105","author":[{"given":"So Yeon","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeji","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daehun","family":"Kwag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gi June","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Ho","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Sik","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Seong","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee-Je","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Goo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoo-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"issue":"4","key":"6999_CR1","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1001\/jamaoncol.2019.5140","volume":"6","author":"E Atallah","year":"2020","unstructured":"Atallah E, Logan B, Chen M, Cutler C, Deeg J, Jacoby M et al (2020) Comparison of patient age groups in transplantation for myelodysplastic syndrome: the Medicare coverage with evidence development study. JAMA Oncol 6(4):486\u2013493. https:\/\/doi.org\/10.1001\/jamaoncol.2019.5140","journal-title":"JAMA Oncol"},{"issue":"30","key":"6999_CR2","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1200\/jco.20.02724","volume":"39","author":"N Kr\u00f6ger","year":"2021","unstructured":"Kr\u00f6ger N, Sockel K, Wolschke C, Bethge W, Schlenk RF, Wolf D et al (2021) Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo study). J Clin Oncol 39(30):3318\u20133327. https:\/\/doi.org\/10.1200\/jco.20.02724","journal-title":"J Clin Oncol"},{"issue":"22","key":"6999_CR3","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","volume":"363","author":"TA Gooley","year":"2010","unstructured":"Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M et al (2010) Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 363(22):2091\u20132101. https:\/\/doi.org\/10.1056\/NEJMoa1004383","journal-title":"N Engl J Med"},{"issue":"3","key":"6999_CR4","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/s41375-018-0302-y","volume":"33","author":"J Schetelig","year":"2019","unstructured":"Schetelig J, de Wree LC, van Gelder M, Koster L, Finke J, Niederwieser D et al (2019) Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia. Leukemia 33(3):686\u2013695. https:\/\/doi.org\/10.1038\/s41375-018-0302-y","journal-title":"Leukemia"},{"issue":"1","key":"6999_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.bbmt.2018.08.004","volume":"25","author":"SS Park","year":"2019","unstructured":"Park SS, Jeon YW, Min GJ, Park S, Yahng SA, Yoon JH et al (2019) Graft-versus-host disease-free, relapse-free survival after allogeneic stem cell transplantation for myelodysplastic syndrome. Biol Blood Marrow Transplant 25(1):63\u201372. https:\/\/doi.org\/10.1016\/j.bbmt.2018.08.004","journal-title":"Biol Blood Marrow Transplant"},{"key":"6999_CR6","doi-asserted-by":"publisher","unstructured":"Hahn T, McCarthy PL Jr., Hassebroek A, Bredeson C, Gajewski JL, Hale GA et al (2013) Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol 31(19):2437\u20132449. https:\/\/doi.org\/10.1200\/jco.2012.46.6193","DOI":"10.1200\/jco.2012.46.6193"},{"issue":"6","key":"6999_CR7","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.bbmt.2014.11.676","volume":"21","author":"J Storek","year":"2015","unstructured":"Storek J, Mohty M, Boelens JJ (2015) Rabbit anti-T cell globulin in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 21(6):959\u2013970. https:\/\/doi.org\/10.1016\/j.bbmt.2014.11.676","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"6999_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1056\/NEJMoa1506002","volume":"374","author":"N Kr\u00f6ger","year":"2016","unstructured":"Kr\u00f6ger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M et al (2016) Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med 374(1):43\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1506002","journal-title":"N Engl J Med"},{"issue":"5","key":"6999_CR9","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3324\/haematol.2020.265769","volume":"107","author":"HT Greinix","year":"2022","unstructured":"Greinix HT, Eikema DJ, Koster L, Penack O, Yakoub-Agha I, Montoto S et al (2022) Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study. Haematologica 107(5):1054\u20131063. https:\/\/doi.org\/10.3324\/haematol.2020.265769","journal-title":"Haematologica"},{"issue":"5","key":"6999_CR10","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/s41409-022-01620-x","volume":"57","author":"E Forcade","year":"2022","unstructured":"Forcade E, Chevret S, Finke J, Ehninger G, Ayuk F, Beelen D et al (2022) Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant 57(5):768\u2013774. https:\/\/doi.org\/10.1038\/s41409-022-01620-x","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"6999_CR11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41409-022-01569-x","volume":"57","author":"S Fuji","year":"2022","unstructured":"Fuji S, Hirakawa T, Takano K, Doki N, Sawa M, Kanda Y et al (2022) Disease-specific impact of anti-thymocyte globulin in allogeneic hematopoietic cell transplantation: a nationwide retrospective study on behalf of the JSTCT, transplant complications working group. Bone Marrow Transplant 57(3):479\u2013486. https:\/\/doi.org\/10.1038\/s41409-022-01569-x","journal-title":"Bone Marrow Transplant"},{"issue":"25","key":"6999_CR12","doi-asserted-by":"publisher","first-page":"6963","DOI":"10.1182\/blood-2011-01-332007","volume":"117","author":"RJ Soiffer","year":"2011","unstructured":"Soiffer RJ, LeRademacher J, Ho V, Kan F, Artz A, Champlin RE et al (2011) Impact of immune modulation with anti\u2013T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 117(25):6963\u20136970. https:\/\/doi.org\/10.1182\/blood-2011-01-332007","journal-title":"Blood"},{"issue":"1","key":"6999_CR13","doi-asserted-by":"publisher","first-page":"40e41","DOI":"10.1016\/j.jtct.2022.09.010","volume":"29","author":"LJ Arcuri","year":"2023","unstructured":"Arcuri LJ, Kerbauy MN, Kerbauy LN, Santos FPS, Ribeiro AAF, Hamerschlak N (2023) ATG in HLA-matched, peripheral blood, hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome: a secondary analysis of a CIBMTR database. Transplantation Cell Therapy 29(1):40e41-40e44. https:\/\/doi.org\/10.1016\/j.jtct.2022.09.010","journal-title":"Transplantation Cell Therapy"},{"issue":"2","key":"6999_CR14","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1016\/s2352-3026(18)30214-x","volume":"6","author":"F Bonifazi","year":"2019","unstructured":"Bonifazi F, Solano C, Wolschke C, Sessa M, Patriarca F, Zallio F et al (2019) Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematol 6(2):e89\u2013e99. https:\/\/doi.org\/10.1016\/s2352-3026(18)30214-x","journal-title":"Lancet Haematol"},{"issue":"5","key":"6999_CR15","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.bbmt.2014.01.016","volume":"20","author":"R Dul\u00e9ry","year":"2014","unstructured":"Dul\u00e9ry R, Mohty M, Duhamel A, Robin M, Beguin Y, Michallet M et al (2014) Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and Cellular Therapy. Biol Blood Marrow Transplant 20(5):646\u2013654. https:\/\/doi.org\/10.1016\/j.bbmt.2014.01.016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"6999_CR16","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1016\/s2352-3026(17)30081-9","volume":"4","author":"J Finke","year":"2017","unstructured":"Finke J, Schmoor C, Bethge WA, Ottinger H, Stelljes M, Volin L et al (2017) Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematol 4(6):e293\u2013e301. https:\/\/doi.org\/10.1016\/s2352-3026(17)30081-9","journal-title":"Lancet Haematol"},{"issue":"2","key":"6999_CR17","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S1470-2045(15)00462-3","volume":"17","author":"I Walker","year":"2016","unstructured":"Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M et al (2016) Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol 17(2):164\u2013173. https:\/\/doi.org\/10.1016\/S1470-2045(15)00462-3","journal-title":"Lancet Oncol"},{"issue":"10","key":"6999_CR18","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1016\/j.bbmt.2020.06.030","volume":"26","author":"J Othman","year":"2020","unstructured":"Othman J, Greenwood M, Moore J, Larsen S, Watson AM, Arthur C et al (2020) Unrelated donor transplant recipients given thymoglobuline have superior GRFS when compared to matched related donor recipients undergoing transplantation without ATG. Biol Blood Marrow Transplant 26(10):1868\u20131875. https:\/\/doi.org\/10.1016\/j.bbmt.2020.06.030","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"6999_CR19","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/ejh.13386","volume":"104","author":"SA Yahng","year":"2020","unstructured":"Yahng SA, Min GJ, Park SS, Park S, Jeon YW, Yoon JH et al (2020) Role of pretransplant anti-thymocyte globulin in matched sibling donor stem cell transplantation after reduced intensity conditioning for myelodysplastic syndrome. Eur J Haematol 104(5):459\u2013468. https:\/\/doi.org\/10.1111\/ejh.13386","journal-title":"Eur J Haematol"},{"issue":"8","key":"6999_CR20","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.leukres.2015.05.003","volume":"39","author":"JM Bastida","year":"2015","unstructured":"Bastida JM, Cabrero M, Lopez-Godino O, Lopez-Parra M, Sanchez-Guijo F, Lopez-Corral L et al (2015) Influence of donor age in allogeneic stem cell transplant outcome in acute myeloid leukemia and myelodisplastic syndrome. Leuk Res 39(8):828\u2013834. https:\/\/doi.org\/10.1016\/j.leukres.2015.05.003","journal-title":"Leuk Res"},{"issue":"5","key":"6999_CR21","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/ajh.26870","volume":"98","author":"C Marcoux","year":"2023","unstructured":"Marcoux C, Marin D, Ramdial J, AlAtrash G, Alousi AM, Oran B et al (2023) Younger haploidentical donor versus older matched unrelated donor for patients with AML\/MDS. Am J Hematol 98(5):712\u2013719. https:\/\/doi.org\/10.1002\/ajh.26870","journal-title":"Am J Hematol"},{"key":"6999_CR22","doi-asserted-by":"publisher","unstructured":"Pereira MP, Remberger M, Chen C, Gerbitz A, Kim DDH, Kumar R et al (2023) Choosing Between Older Matched Sibling Donor and Younger Matched Unrelated Donor in Allogeneic Hematopoietic Cell Transplantation: Comparison of Clinical Outcomes in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Transplant Cell Ther 29(11): 697.e691-697.e610. e-pub ahead of print 20230812.\u00a0https:\/\/doi.org\/10.1016\/j.jtct.2023.08.009","DOI":"10.1016\/j.jtct.2023.08.009"},{"issue":"1","key":"6999_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0502-3","volume":"10","author":"YJ Chang","year":"2017","unstructured":"Chang YJ, Wang Y, Liu YR, Xu LP, Zhang XH, Chen H et al (2017) Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. J Hematol Oncol 10(1):134. https:\/\/doi.org\/10.1186\/s13045-017-0502-3","journal-title":"J Hematol Oncol"},{"issue":"4","key":"6999_CR24","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1200\/jco.2007.11.1641","volume":"26","author":"D Valc\u00e1rcel","year":"2008","unstructured":"Valc\u00e1rcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB et al (2008) Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 26(4):577\u2013584. https:\/\/doi.org\/10.1200\/jco.2007.11.1641","journal-title":"J Clin Oncol"},{"key":"6999_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/20406207211043748","volume":"12","author":"S Park","year":"2021","unstructured":"Park S, Kim TY, Lee JH, Lee JY, Min GJ, Park SS et al (2021) Differential effects of donor lymphocyte infusion upon treatment response and GVHD according to relapse level and donor sources in patients with myelodysplastic syndrome. Ther Adv Hematol 12:20406207211043748. https:\/\/doi.org\/10.1177\/20406207211043748","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"6999_CR26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U et al (2016) International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant 22(1):4\u201310. https:\/\/doi.org\/10.1016\/j.bbmt.2015.09.001","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"6999_CR27","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW et al (2015) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. the 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant 21(3):389-401.e381. https:\/\/doi.org\/10.1016\/j.bbmt.2014.12.001","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"6999_CR28","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1001\/jamaoncol.2021.6846","volume":"8","author":"GS Guru Murthy","year":"2022","unstructured":"Guru Murthy GS, Kim S, Hu ZH, Estrada-Merly N, Abid MB, Aljurf M et al (2022) Relapse and disease-free survival in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation using older matched sibling donors vs younger matched unrelated donors. JAMA Oncol 8(3):404\u2013411. https:\/\/doi.org\/10.1001\/jamaoncol.2021.6846","journal-title":"JAMA Oncol"},{"issue":"3","key":"6999_CR29","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/leu.2012.210","volume":"27","author":"N Kr\u00f6ger","year":"2013","unstructured":"Kr\u00f6ger N, Zabelina T, de Wree L, Berger J, Alchalby H, van Biezen A et al (2013) Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings. Leukemia 27(3):604\u2013609. https:\/\/doi.org\/10.1038\/leu.2012.210","journal-title":"Leukemia"},{"issue":"9","key":"6999_CR30","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.bbmt.2015.04.024","volume":"21","author":"CCS Yeung","year":"2015","unstructured":"Yeung CCS, Gerds AT, Fang M, Scott BL, Flowers MED, Gooley T et al (2015) Relapse after allogeneic hematopoietic cell transplantation for myelodysplastic syndromes: analysis of late relapse using comparative karyotype and chromosome genome array testing. Biol Blood Marrow Transplant 21(9):1565\u20131575. https:\/\/doi.org\/10.1016\/j.bbmt.2015.04.024","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"6999_CR31","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1182\/blood-2013-04-496778","volume":"122","author":"W Saber","year":"2013","unstructured":"Saber W, Cutler CS, Nakamura R, Zhang MJ, Atallah E, Rizzo JD et al (2013) Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). Blood 122(11):1974\u20131982. https:\/\/doi.org\/10.1182\/blood-2013-04-496778","journal-title":"Blood"},{"issue":"29","key":"6999_CR32","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1200\/jco.20.00150","volume":"38","author":"Y-J Chang","year":"2020","unstructured":"Chang Y-J, Wu D-P, Lai Y-R, Liu Q-F, Sun Y-Q, Hu J et al (2020) Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: a multicenter, open-label, randomized controlled study. J Clin Oncol 38(29):3367\u20133376. https:\/\/doi.org\/10.1200\/jco.20.00150","journal-title":"J Clin Oncol"},{"issue":"11","key":"6999_CR33","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1182\/blood.2019000487","volume":"134","author":"G Battipaglia","year":"2019","unstructured":"Battipaglia G, Labopin M, Kr\u00f6ger N, Vitek A, Afanasyev B, Hilgendorf I et al (2019) Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. Blood 134(11):892\u2013899. https:\/\/doi.org\/10.1182\/blood.2019000487","journal-title":"Blood"},{"issue":"1","key":"6999_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01032-8","volume":"14","author":"O Penack","year":"2024","unstructured":"Penack O, Abouqateb M, Peczynski C, Boreland W, G\u00fclbas Z, Gedde-Dahl T et al (2024) PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation. Blood Cancer J 14(1):45. https:\/\/doi.org\/10.1038\/s41408-024-01032-8","journal-title":"Blood Cancer J"},{"issue":"2","key":"6999_CR35","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3324\/haematol.2016.151779","volume":"102","author":"A Ruggeri","year":"2017","unstructured":"Ruggeri A, Sun Y, Labopin M, Bacigalupo A, Lorentino F, Arcese W et al (2017) Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus -host disease prophylaxis in haploidentical transplant. Haematologica 102(2):401\u2013410. https:\/\/doi.org\/10.3324\/haematol.2016.151779","journal-title":"Haematologica"},{"issue":"28","key":"6999_CR36","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1200\/jco.24.00184","volume":"42","author":"BC Shaffer","year":"2024","unstructured":"Shaffer BC, Gooptu M, DeFor TE, Maiers M, Bola\u00f1os-Meade J, Abboud R et al (2024) Post-transplant cyclophosphamide\u2013based graft-versus-host disease prophylaxis attenuates disparity in outcomes between use of matched or mismatched unrelated donors. J Clin Oncol 42(28):3277\u20133286. https:\/\/doi.org\/10.1200\/jco.24.00184","journal-title":"J Clin Oncol"},{"issue":"25","key":"6999_CR37","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","volume":"388","author":"J Bola\u00f1os-Meade","year":"2023","unstructured":"Bola\u00f1os-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L et al (2023) Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med 388(25):2338\u20132348. https:\/\/doi.org\/10.1056\/NEJMoa2215943","journal-title":"N Engl J Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06999-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06999-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06999-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:21:15Z","timestamp":1778750475000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06999-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["6999"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06999-x","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"260"}}